View in EDS

A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients

Saved in:
Bibliographic Details
Title: A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients
Authors: Seoyeon Jung, Jaeyeon Kim, Jin Hoo Park, Ki-Yeol Kim, Hyung Jun Kim, Wonse Park
Contributors: Seoyeon Jung, Jaeyeon Kim, Jin Hoo Park, Ki-Yeol Kim, Hyung Jun Kim, Wonse Park, Kim, Hyung Jun
Source: Sci Rep
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Publisher Information: Springer Science and Business Media LLC, 2022.
Publication Year: 2022
Subject Terms: 0301 basic medicine, Bone Density Conservation Agents, Diphosphonates, Osteonecrosis* / chemically induced, Science, Osteonecrosis, Bone Density Conservation Agents / adverse effects, Article, Denosumab* / adverse effects, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Diphosphonates / adverse effects, Osteoporosis* / drug therapy, Medicine, Humans, Osteoporosis, Bisphosphonate-Associated Osteonecrosis of the Jaw, Denosumab, Retrospective Studies
Description: Denosumab has been suggested as a first-line therapy for osteoporotic patients. However, a standardized protocol for the prevention of denosumab induced medication-related osteonecrosis of the jaw (MRONJ) has not yet been established. The purpose of this study was to report denosumab induced MRONJ cases, and investigate the factors affecting the occurrence of MRONJ in patients who underwent denosumab and invasive dental treatment (especially tooth extraction) between October 2016 and March 2020. Four of the 98 patients developed MRONJ before and after tooth extraction. The participants were divided into two groups: receiving only denosumab (n = 51) and receiving bisphosphonate as first treatment and denosumab as second treatment (n = 47). There was no significant difference between groups in the occurrence of MRONJ and factors affecting MRONJ. Two out of 4 patients developed MRONJ regardless of invasive treatment after denosumab administration and proceeded with extraction; one patient developed MRONJ after denosumab administration and extraction. The other patient underwent a tooth extraction without osteoporosis treatment, and non-identified MRONJ developed after denosumab administration. MRONJ cases reported in this study show that MRONJ can develop as chronic inflammation without invasive dental treatment; therefore, implementing preventive dental treatment before initiating denosumab treatment is necessary to reduce the occurrence of MRONJ.
Document Type: Article
Other literature type
Language: English
ISSN: 2045-2322
DOI: 10.1038/s41598-022-11615-9
Access URL: https://pubmed.ncbi.nlm.nih.gov/35606457
https://doaj.org/article/1dafe85ac798454e8523ad0759373ea3
Rights: CC BY
CC BY NC ND
Accession Number: edsair.doi.dedup.....2939d40998b50e28e30d97a81ea40555
Database: OpenAIRE
Description
Abstract:Denosumab has been suggested as a first-line therapy for osteoporotic patients. However, a standardized protocol for the prevention of denosumab induced medication-related osteonecrosis of the jaw (MRONJ) has not yet been established. The purpose of this study was to report denosumab induced MRONJ cases, and investigate the factors affecting the occurrence of MRONJ in patients who underwent denosumab and invasive dental treatment (especially tooth extraction) between October 2016 and March 2020. Four of the 98 patients developed MRONJ before and after tooth extraction. The participants were divided into two groups: receiving only denosumab (n = 51) and receiving bisphosphonate as first treatment and denosumab as second treatment (n = 47). There was no significant difference between groups in the occurrence of MRONJ and factors affecting MRONJ. Two out of 4 patients developed MRONJ regardless of invasive treatment after denosumab administration and proceeded with extraction; one patient developed MRONJ after denosumab administration and extraction. The other patient underwent a tooth extraction without osteoporosis treatment, and non-identified MRONJ developed after denosumab administration. MRONJ cases reported in this study show that MRONJ can develop as chronic inflammation without invasive dental treatment; therefore, implementing preventive dental treatment before initiating denosumab treatment is necessary to reduce the occurrence of MRONJ.
ISSN:20452322
DOI:10.1038/s41598-022-11615-9